SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells

被引:0
|
作者
Parameet Kumar
Dharmendra Kumar Soni
Chaitali Sen
Mads B. Larsen
Krystyna Mazan-Mamczarz
Yulan Piao
Supriyo De
Myriam Gorospe
Raymond A. Frizzell
Roopa Biswas
机构
[1] School of Medicine,Department of Anatomy, Physiology and Genetics
[2] Uniformed Services University of the Health Sciences,Department of Cell Biology
[3] University of Pittsburgh,Laboratory of Genetics and Genomics
[4] School of Medicine,Department of Anatomy, Physiology and Genetics
[5] National Institute on Aging,undefined
[6] National Institutes of Health,undefined
[7] School of Medicine,undefined
[8] Uniformed Services University of the Health Sciences,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cystic fibrosis (CF) occurs as a result of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which lead to misfolding, trafficking defects, and impaired function of the CFTR protein. Splicing factor proline/glutamine-rich (SFPQ) is a multifunctional nuclear RNA-binding protein (RBP) implicated in the regulation of gene expression pathways and intracellular trafficking. Here, we investigated the role of SFPQ in the regulation of the expression and function of F508del-CFTR in CF lung epithelial cells. We find that the expression of SFPQ is reduced in F508del-CFTR CF epithelial cells compared to WT-CFTR control cells. Interestingly, the overexpression of SFPQ in CF cells increases the expression as well as rescues the function of F508del-CFTR. Further, comprehensive transcriptome analyses indicate that SFPQ plays a key role in activating the mutant F508del-CFTR by modulating several cellular signaling pathways. This is the first report on the role of SFPQ in the regulation of expression and function of F508del-CFTR in CF lung disease. Our findings provide new insights into SFPQ-mediated molecular mechanisms and point to possible novel epigenetic therapeutic targets for CF and related pulmonary diseases.
引用
收藏
相关论文
共 50 条
  • [41] Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
    Amico, Giulia
    Brandas, Chiara
    Moran, Oscar
    Baroni, Debora
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
  • [42] F508del-CFTR is not corrected by thymosin α1
    Elizabeth Matthes
    John W. Hanrahan
    André M. Cantin
    Nature Medicine, 2018, 24 : 890 - 891
  • [43] F508del-CFTR is not corrected by thymosin α1
    Matthes, Elizabeth
    Hanrahan, John W.
    Cantin, Andre M.
    NATURE MEDICINE, 2018, 24 (07) : 890 - 891
  • [44] CHEMICAL MODULATION OF F508DEL-CFTR UNFOLDING
    Bear, Christine
    Eckford, Paul
    Li, Canhui
    Huan, Ling-Jun
    Chin, Stephanie
    Gonska, Tanja
    Molinski, Steven
    Pasyk, Stan
    Ahmadi, Saumel
    Ramjeesingh, Mohabir
    PEDIATRIC PULMONOLOGY, 2012, 47 : 144 - 145
  • [45] INHIBITION OF HSP90/F508DEL-CFTR INTERACTION BY ISOLAB LEADS TO THE RESTORATION OF THE MUTATED PROTEIN TO THE PLASMA MEMBRANE IN CYSTIC FIBROSIS EPITHELIAL CELLS
    Bertrand, J.
    Boinot, C.
    Mouzannar, K.
    Fleet, G.
    Meyer, P.
    Becq, F.
    Norez, C.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 219 - 220
  • [46] An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)
    Flume, P.
    Biner, Fischer R.
    Downey, D. G.
    Brown, C.
    Jain, M.
    Fischer, R.
    de Boeck, C.
    Campbell, D.
    Wang, X.
    Ahluwalia, N.
    Owen, C. A.
    Wainwright, C.
    PNEUMOLOGIE, 2020, 74 : S87 - S87
  • [47] Abnormal spatial diffusion of Ca2+ in F508del-CFTR airway epithelial cells
    Fabrice Antigny
    Caroline Norez
    Anne Cantereau
    Frédéric Becq
    Clarisse Vandebrouck
    Respiratory Research, 9
  • [48] Abnormal spatial diffusion of Ca2+ in F508del-CFTR airway epithelial cells
    Antigny, Fabrice
    Norez, Caroline
    Cantereau, Anne
    Becq, Frederic
    Vandebrouck, Clarisse
    RESPIRATORY RESEARCH, 2008, 9 (1):
  • [49] Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR
    Donaldson, Scott H.
    Solomon, George M.
    Zeitlin, Pamela L.
    Flume, Patrick A.
    Casey, Alicia
    McCoy, Karen
    Zemanick, Edith T.
    Mandagere, Arun
    Troha, Janice M.
    Shoemaker, Steven A.
    Chmiel, James F.
    Taylor-Cousar, Jennifer L.
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (03) : 371 - 379
  • [50] EFFECT OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS WHO ARE HOMOZYGOUS FOR F508DEL-CFTR: TRANSPORT STUDY
    Ramsey, B.
    Boyle, M. P.
    Elborn, J.
    Huang, X.
    Marigowda, G.
    Waltz, D.
    Wainwright, C. E.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 305 - 305